All In Biotech

Drug Trial Radar · NCT03671967

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Piperacillin Tazobactam Versus Meropenem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae- a Non-inferiority Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Aug 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 1,084 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,084

Planned (sponsor's estimate)

Start

May 1, 2019

Primary completion

Jan 1, 2027

Study completion Apr 1, 2027

Sponsor

Lead sponsor
Rambam Health Care CampusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Rabin Medical Center; University of Modena and Reggio Emilia; Tel Aviv Medical Center; Meir Medical Center; Soroka University Medical Center; The Chaim Sheba Medical Center; McGill University Health Centre/Research Institute of the McGill University Health Centre; Jewish General Hospital; Canadian Institutes of Health Research (CIHR); Hadassah Medical Organization
First posted
Sep 14, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Data regarding optimal treatment for extended-spectrum beta-lactamase (ESBL) producing Enterobacteriaceae blood-stream infection are lacking. Observational studies show conflicting results when comparing treatment with combination beta-lactam-beta-lactamase inhibitor and carbapenems. The investigators aim to evaluate the effect of definitive treatment with meropenem vs. piperacillin-tazobactam on the outcome of patients with bacteremia due to cephalosporin-non-susceptible Enterobacteriaceae. The investigators hypothesize that piperacillin-tazobactam is non-inferior to meropenem.

Conditions

  • Beta Lactam Resistant Bacterial Infection
  • Enterobacteriaceae Infections
  • Bacteremia

Interventions

  • Piperacillin/tazobactamDrug

    4.5 grams QID

  • MeropenemDrug

    1 gram TID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All-cause mortalityTime frame: 30 days from randomization
  2. Treatment failureTime frame: 7 days from randomization

Locations

14 sites in 2 countries. Site status is shown where the registry gives one.

  • McGill University Health Centre

    Montreal, Quebec, Canada · Recruiting

  • University of Calgary, Cumming School of Medicine, O'Brien Institute for Public Health

    Calgary, Alberta, Canada · Recruiting

  • Surrey Memorial Hospital - Fraser Health Authority

    Surrey, British Columbia, Canada · Recruiting

  • Eastern Health

    St. John's, Newfoundland and Labrador, Canada · Recruiting

  • Kingston General Hospital

    Kingston, Ontario, Canada · Recruiting

  • Jewish Genral Hospital

    Montreal, Quebec, Canada · Recruiting

  • Soroka Medical Center

    Beersheba, Israel · Recruiting

  • Hadassah Medical Center

    Jerusalem, Israel · Recruiting

  • Meir Medical Center

    Kfar Saba, Israel · Recruiting

  • Sanz Medical Center-Laniado Hospital

    Netanya, Israel · Recruiting

  • Rabin Medical Center, Beilinson Campus

    Petah Tikva, Israel · Recruiting

  • Sheba Medical Center (Tel HaShomer)

    Tel Aviv, Israel · Recruiting

  • Sourasky Medical Center

    Tel Aviv, Israel · Recruiting

  • Rambam Health Care Campus

    Haifa, Israel, Israel · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.